ArticleAnnals of surgical oncology2026
Do Tumor Deposits Demand More? Association of Chemotherapy Regimen Intensity with Survival Outcomes in N1 Colon Cancer Patients with Tumor Deposits.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic divergence of hematogenous and lymphatic metastases in surgically treated patients with stage IV colorectal cancer.International journal of colorectal disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor deposits (TDs) in stage III colon cancer are associated with worse outcomes, yet the American Joint Committee on Cancer (AJCC) Tumor Node Metastasis (TNM) system only accounts for TDs as N1c in the absence of positive lymph nodes. The Sassun-Mayo staging system integrates TDs with nodal count, often upstaging N1 patients to N2; however, therapeutic implications remain unclear as chemotherapy regimens differ between stages.
methodsThis retrospective, multicenter, cohort study included patients with AJCC stage III N1 colon adenocarcinoma with one or more TD. Exclusion criteria were age >75 years, inadequate chemotherapy, and no follow-up. Patients were categorized as 'treated as N1' (3 months of FOLFOX or 6 months of capecitabine/5-fluorouracil) versus 'treated as N2' (6 months of FOLFOX or 3-6 months of XELOX).
resultsIn total, 110 patients were included; 27 (25%) were treated as N1, and 83 (75%) were treated as N2, with balanced baseline characteristics. Patients receiving N2-level chemotherapy had better 5-year outcomes than receiving N1 chemotherapy protocols. Overall survival was 87.5% versus 67.6% (p = 0.010), and disease-free survival was 81.3% versus 61.2% (p = 0.023). In multivariable analyses adjusted for pT stage, N2-level therapy was associated with a lower risk of death (hazard ratio [HR] 0.31; 95% confidence interval [CI] 0.12-0.79; p = 0.015) and recurrence (HR 0.41; 95% CI 0.19-0.92; p = 0.031). We found that 3-6 months of XELOX yielded the highest disease-free survival, whereas capecitabine/5-fluorouracil and 3 months of FOLFOX were associated with the poorest outcomes.
conclusionsPatients with TD-positive N1 colon cancer may benefit from N2-level chemotherapy. Incorporating TDs into nodal count may refine prognostic accuracy and improve treatment selection, potentially warranting updates to staging guidelines.
Indexed as
Identifiers
41566128What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.